Business Wire

XPeng Inc. Announces Pricing of Global Offering

Share

XPeng Inc. (“XPeng” or the “Company”) (NYSE: XPEV, HKEX:9868.HK), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced the pricing of the global offering (the “Global Offering”) of 85,000,000 shares (the “Offer Shares”) which comprises an international offering (the “International Offering”) and a Hong Kong public offering (the “Hong Kong Public Offering”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005570/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The XPeng P7 fleet (Photo: Business Wire)

The final offer price for both the International Offering and the Hong Kong Public Offering (the "Offer Price") has been set at HK$165.00 per Class A ordinary share. Based on the ratio of two Class A ordinary shares per NYSE-listed American depositary share (the "ADS"), the Offer Price translates to approximately US$42.52 per ADS based on an exchange rate of HK$7.7604 to US$1.00. Subject to approval from The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”), the Class A ordinary shares are expected to begin trading on the Main Board of the Hong Kong Stock Exchange on Wednesday, July 7, 2021, under the stock code "9868".

The gross proceeds to the Company from the Global Offering, before deducting underwriting fees and the offering expenses, are expected to be approximately HK$14,025.0 million (assuming the Over-allotment Option is not exercised). In addition, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Representatives (and on behalf of the International Underwriters), at any time on or before Friday, July 30, 2021, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, pursuant to which the Company may be required to issue up to an aggregate of 12,750,000 Class A ordinary shares at the Offer Price.

The Company plans to use the net proceeds from the Global Offering for expansion of its product portfolio and development of more advanced technology; acceleration of its business expansion, by enhancing brand recognition, acquiring customers through omni-channel marketing strategies and expanding its sales and service touch points both domestically and internationally; enhancement of production capability, including expansion of capacity, upgrade of manufacturing facilities and development of manufacturing technologies; and general corporate purposes, including working capital needs.

J.P. Morgan Securities (Far East) Limited and Merrill Lynch (Asia Pacific) Limited are the Joint Sponsors of the listing of the Offer Shares on the Hong Kong Stock Exchange. J.P. Morgan Securities (Asia Pacific) Limited, Merrill Lynch (Asia Pacific) Limited and Citigroup Global Markets Asia Limited are the Joint Representatives. J.P. Morgan Securities (Asia Pacific) Limited, Merrill Lynch (Asia Pacific) Limited, Citigroup Global Markets Asia Limited and CLSA Limited are the Joint Global Coordinators of the Global Offering.

The Company’s registration statement on Form F-1 relating to the International Offering has been filed with, and declared effective by, the United States Securities and Exchange Commission (the “SEC”). The International Offering is being made only by means of a prospectus forming part of the effective registration statement. The registration statement on Form F-1, which contains a preliminary prospectus dated June 24, 2021, is available at the SEC’s website at www.sec.gov. The final prospectus will be filed with the SEC and will be available on the SEC’s website at: http://www.sec.gov. When available, copies of the final prospectus relating to the offering may also be obtained from J.P. Morgan Securities LLC, by telephone at +1 (866) 803-9204 or by email at prospectus-eq_fi@jpmchase.com; and BofA Securities, Inc., by telephone at +1 (800) 294-1322, or by email at dg.prospectus_requests@bofa.com.

The price of the Offer Shares of the Company may be stabilized in accordance with the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). The details of the intended stabilization and how it will be regulated under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) have been contained in the prospectus of the Company dated June 25, 2021.

The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

About XPeng Inc.

XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers in China. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrification/electronic architecture. XPeng is headquartered in Guangzhou, China, with offices in Beijing, Shanghai, Silicon Valley and San Diego. The Company’s Smart EVs are manufactured at plants in Zhaoqing and Zhengzhou, located in Guangdong and Henan provinces, respectively. For more information, please visit https://en.xiaopeng.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Statements that are not historical facts, including statements about XPeng’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: XPeng’s goals and strategies; XPeng’s expansion plans; XPeng’s future business development, financial condition and results of operations; the trends in, and size of, China’s EV market; XPeng’s expectations regarding demand for, and market acceptance of, its products and services; XPeng’s expectations regarding its relationships with customers, contract manufacturers, suppliers, third-party service providers, strategic partners and other stakeholders; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in XPeng’s filings with the SEC. All information provided in this press release is as of the date of this press release, and XPeng does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Important Disclaimers

1. The proposed Global Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Global Offering may be completed, or as to the actual size or terms of the Global Offering.

2. This press release is for information purposes only and does not constitute or include any recommendation or invitation or offer (nor is calculated to invite such a recommendation, offer or invitation) by any person for acquisition, purchase or subscription of the securities of the Company nor does it intend to act as a recommendation of the sale of securities or any invitation, solicitation or offer for acquisition, purchase or subscription of securities in any jurisdiction. This press release should accordingly not amount to an advertisement or invitation within the meaning of section 103(1) of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) or a prospectus or an extract from or abridged version of a prospectus (including within the meaning of sections 2 and 38B, respectively of the Companies (Winding Up and Miscellaneous Provisions) Ordinance). Investors should read the prospectus of the Company for detailed information about the Company and the proposed offering before deciding whether or not to purchase any securities of the Company. This press release has not been reviewed or approved by The Stock Exchange of Hong Kong Limited or the Securities and Futures Commission of Hong Kong. An application to subscribe for the shares for the Hong Kong Public Offering referred to in this press release by any persons shall be made solely based on the prospectus and the application forms issued by the Company on June 25, 2021.

3. No application for the shares of the Company should be made by any person nor would such application be accepted without the completion of a formal application form or other application procedure that is issued with or in respect of the prospectus.

4. The directors of the Company collectively and individually accept full responsibility for the accuracy of the information contained in this press release and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts the omission of which would make any statement herein misleading.

This press release is issued by Wonderful Sky Financial Group Ltd. on behalf of XPeng Inc.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Investor Enquiries:
IR Department
XPeng Inc.
Email: ir@xiaopeng.com

Jenny Cai
The Piacente Group
Tel: +1 212 481 2050 / +86 10 6508 0677
Email: xpeng@tpg-ir.com

For Media Enquiries:
Marie Cheung
XPeng Inc.
Tel: +852 9750 5170 / +86 1550 7577 546
Email: mariecheung@xiaopeng.com

Media Relations
For further information, please contact:
Wonderful Sky Financial Group Ltd.
Angie Li / Jerry Lou / Cici Zhu
Tel: +852 3970 2273 / +852 3970 2157 / +852 3977 1854
Email: angieliy@wsfg.hk / jerrylouzh@wsfg.hk / CiciZhuX@wsfg.hk

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SES Networks Expands Partnership With Orange to Enhance Maritime Services3.8.2021 08:50:00 CEST | Press release

Orange maritime customers will now be able to accelerate their digital transformation with higher-capacity satellite connectivity services provided jointly by SES Networks and Orange. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005841/en/ SES Networks Expands Partnership With Orange to Enhance Maritime Services (Photo: Business Wire) With this innovative agreement, Orange will integrate its own global infrastructure with the global network coverage powered by SES Networks’ Skala Global Platform. Together it will enable Orange maritime customers to cost-effectively scale up their bandwidth with seamless, ubiquitous and global services. This will ensure they can implement new technologies onboard that take advantage of IoT and AI, as well as edge and cloud applications. The combination of the Orange secured and digital network infrastructure and SES Networks’ Skala Global Platform -- a next-generation technology platf

Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis3.8.2021 07:03:00 CEST | Press release

RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief” or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that, via its newly acquired subsidiary, AdVita Lifescience GmbH, the Company has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”) for RLF-100 (aviptadil), an inhaled formulation in development for the treatment of sarcoidosis. RLF-100 is a synthetic form of vasoactive intestinal peptide. In open label exploratory clinical experience in sarcoidosis patients, RLF-100 has been shown to be well tolerated and safe, and to produce favorable immunoregulatory effects in the lungs that have been associated with symptom relief in a significant proportion of the patients. “Receipt of our third Orphan Drug Designation is another important milestone for the Company, as it underscores the potential strength of our pipeline and the high need for be

Smart Engages P.I. Works for Expanded Network Automation Solution3.8.2021 07:00:00 CEST | Press release

Smart Communications, Inc. (Smart), the wireless unit of the Philippines’ largest, fully integrated telecommunications company PLDT, has partnered with P.I. Works for a comprehensive strategy for its Self-Organizing Network (SON) Solution to automate its multi-vendor, multi-technology networks. A self-organizing network (SON) is an automation technology designed to make the planning, configuration, performance management, coverage and quality optimization and healing of mobile radio access networks efficient, simpler and faster. This automation is expected to significantly improve the performancemanagement and service quality enhancements of the Smart wireless network, which will result in an improved experience for Smart customers across the country. Under its Network Operations Transformation program, Smart started working with P.I. Works in 2018 through another entity, to enable Artificial Intelligence (AI) and Machine Learning (ML) technologies for the automation of various network

Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients2.8.2021 22:05:00 CEST | Press release

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study "Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms,"(1) in Clinical Cancer Research, a journal published by the American Association for Cancer Research. The study details the development of the Personalis Neoantigen Presentation Score (NEOPS™), a novel composite biomarker for predicting response to cancer immunotherapy. Enabled by comprehensive tumor immunogenomic profiling from the Personalis NeXT Platform, NEOPS simultaneously models both neoantigen burden and immune-related resistance mechanisms to better predict immunotherapy response in a cohort of late-stage melanoma patients. In this study, NEOPS was more strongly predictive of therapy response than other standard single analyte and investigational biomarkers tested, including tumor mutational b

The Consortium Welcomes Playtech’s Confirmed Recommendation for Its Binding Agreement to Acquire Finalto and Urges Investors to Vote in Favour at the Playtech Adjourned General Meeting on 18 August 20212.8.2021 19:41:00 CEST | Press release

Finalto S.P.V. Ltd, the consortium led by Barinboim Group and backed by Leumi Partners Limited and Menora Mivtachim Group, together with key members of the Finalto Business' management team (together the "Consortium"), welcomes the announcement by Playtech plc (“Playtech”) confirming its recommendation that shareholders vote in favour of the Consortium’s binding agreement for Finalto Group (“Finalto) (the “Binding Agreement”). Playtech announced today that following its engagement with Gopher Investments (“Gopher”) over the past three weeks, it has not received responses from Gopher to a number of its questions and therefore “Playtech has not yet been able to achieve the necessary clarity on Gopher's ultimate ownership and funding structure, source of funds or ability to obtain the required regulatory clearances”. Shareholders should ask why Gopher continues to hide and should also be suspicious of Gopher’s credibility, particularly given that disclosure is crucial when buying a highly

Lenovo Climbs 65 Places to Record #159 On ‘FORTUNE Global 500’ List2.8.2021 17:09:00 CEST | Press release

After achieving historical 2021 fiscal year results, Lenovo has been ranked #159 on FORTUNE’s annual Global 500 List and in the top 20 (#15) of all Technology sector companies cited in the List. Lenovo jumped 65 spots this year to an all-time high ranking due to its record financial results, which saw the Group surge past the US$60 billion revenue mark, and adding more than US$10 billion from the previous fiscal year as all core businesses grew. The Fortune Global 500 is the annual ranking of the largest 500 corporations in the world as measured by total revenue. Together, companies on The Global 500 generated US$31.7 trillion in revenue and US$1.6 trillion in profits in 2020, employ 69.7 million people worldwide and are represented by 31 countries. Lenovo’s updated ranking reflects the company’s clear strategy, product innovation, operational excellence, and global/local footprint within the past year. These results reinforced the company’s resilience and ability to achieve balanced,

From Panasonic i-PRO Sensing Solutions to “i-PRO”, Renewing Its Company Name From April 20222.8.2021 17:00:00 CEST | Press release

Panasonic i-PRO Sensing Solutions Co., Ltd. will renew its company name to "i-PRO Co., Ltd." on April 1, 2022. Our company was established in October 2019 as a business separation from Panasonic Corporation, and we have incorporated the network camera brand "i-PRO" into our company name. With the new brand "i-PRO", we have been developing and delivering products that incorporate various innovations to our customers, with "Extend human senses through technology, to capture moments of truth so the front-line professionals can act." as our brand purpose for our existence in society. With our global headquarters located in Japan, we will continue our daily efforts to innovate and develop a range of products under the global brand name "i-PRO", which will be launched in markets around the world. In advance of it, i-PRO EMEA B.V. will be headquartered in Amsterdam and start operations as of October 1st, 2021, in the transition of its European Security and Industrial Medical Vision (IMV) busi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom